Published in J Neural Transm (Vienna) on October 01, 2003
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc (2009) 2.06
Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain (2009) 2.04
Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) (2007) 1.94
Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition. Brain (2008) 1.29
Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol (2008) 1.18
Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation. PLoS Comput Biol (2006) 1.18
Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep (2010) 1.13
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.11
Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology (Berl) (2013) 0.97
The dopamine agonist bromocriptine differentially affects fronto-striatal functional connectivity during working memory. Front Hum Neurosci (2011) 0.91
Effects of pramipexole on impulsive choice in male wistar rats. Exp Clin Psychopharmacol (2010) 0.90
The effect of dopamine agonists on adaptive and aberrant salience in Parkinson's disease. Neuropsychopharmacology (2011) 0.89
Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry (2011) 0.85
Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males. Psychopharmacology (Berl) (2007) 0.84
Clinical and imaging features of Othello's syndrome. Eur J Neurol (2011) 0.83
Dopamine agonists and pathologic behaviors. Parkinsons Dis (2012) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol (2013) 0.82
Feeding condition and the relative contribution of different dopamine receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology (Berl) (2013) 0.82
Dopaminergic influences on emotional decision making in euthymic bipolar patients. Neuropsychopharmacology (2013) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci (2014) 0.82
TMS-assisted neurophysiological profiling of the dopamine receptor agonist cabergoline in human motor cortex. J Neural Transm (Vienna) (2006) 0.81
The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Funct Neurol (2013) 0.81
Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. J Neural Transm (Vienna) (2010) 0.80
Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. Biomed Res Int (2014) 0.80
Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord (2013) 0.80
Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.78
A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view. J Neural Transm (Vienna) (2006) 0.76
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. Clin Interv Aging (2012) 0.76
Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. J Neural Transm (Vienna) (2005) 0.75
Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans. J Neurosci (2017) 0.75
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Antiglucocorticoid effects of DHEA-S in Alzheimer's disease. Am J Psychiatry (1992) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol (1991) 1.26
Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm (1976) 1.26
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res (1999) 1.24
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J Neuroimmunol (2007) 1.23
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23
Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem (1997) 1.21
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl (1994) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol (2000) 1.10
Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol (2001) 1.10
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett (2000) 1.10
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett (1999) 1.08
Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm (Vienna) (2000) 1.08
Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol (2004) 1.08
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm (Vienna) (2004) 1.06
Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J Neural Transm (Vienna) (2000) 1.06
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res (1996) 1.06
Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm (Vienna) (1998) 1.06
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry (1997) 1.05
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry (2001) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry (1995) 1.04
Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect (1993) 1.03
Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl (2006) 1.03
High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett (1999) 1.03
Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg (1979) 1.03
Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neurol (1984) 1.03
A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci (1999) 1.03
Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev (1997) 1.02
The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res (2000) 1.02
Parkinsonism in HIV dementia. J Neural Transm (Vienna) (2002) 1.02
Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol (1991) 1.02
Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci (1996) 1.01
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol (1989) 1.01
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology (2001) 1.01
Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) (2010) 1.01
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (2001) 1.00
Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat (2000) 1.00
Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm (Vienna) (2003) 1.00
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl (1989) 0.99
Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet (2001) 0.99
Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci (2000) 0.99
Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol (1999) 0.99
Neuronal and ependymal expression of selenoprotein P in the human brain. J Neural Transm (Vienna) (2007) 0.99
Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm (Vienna) (2003) 0.99
Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm (Vienna) (2002) 0.98
Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect (1993) 0.98
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Brain monoamines in human hepatic encephalopathy. Acta Neuropathol (1978) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Persistence of haloperidol in human brain tissue. Am J Psychiatry (1999) 0.98